Caliber Biotherapeutics and iBio agreed to jointly develop and produce recombinant plant-based biopharmaceuticals using Caliber's plant-based production expertise and the iBioLaunch platform. The partners will initially work on a monoclonal antibody for cancer. iBio will get license and milestone fees and sales royalties on products arising from the collaboration.
Firms ally to develop plant-based drugs
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||